AGIO 8-K 2026-11-05

AGIOS PHARMACEUTICALS, INC. (AGIO) 8-K dated 2026-11-05 — accession 0001439222-26-000129.

AGIOS PHARMACEUTICALS, INC. (AGIO) is a biotechnology company listed on US.

AGIO: Agios Reports Third Quarter 2026 Financial Results and Provides Busines…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported AGIO revenue for 2025-12-31 was $54.0M. Net income was -$412.8M. Revenue was up 48.0% from 2024-12-31 to 2025-12-31. AGIO currently screens at market cap $1.68B.

Not investment advice. The AGIO SEC hub lists recent forms. The stock page is the research view.